Overview Long Term Safety Assessment of SER120 in Patients With Nocturia Status: Completed Trial end date: 2011-08-01 Target enrollment: Participant gender: Summary The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients. Phase: Phase 3 Details Lead Sponsor: Serenity Pharmaceuticals, Inc.